AU3846801A - Aspirin-triggered lipid mediators - Google Patents

Aspirin-triggered lipid mediators

Info

Publication number
AU3846801A
AU3846801A AU3846801A AU3846801A AU3846801A AU 3846801 A AU3846801 A AU 3846801A AU 3846801 A AU3846801 A AU 3846801A AU 3846801 A AU3846801 A AU 3846801A AU 3846801 A AU3846801 A AU 3846801A
Authority
AU
Australia
Prior art keywords
aspirin
lipid mediators
triggered lipid
triggered
mediators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU3846801A
Other languages
English (en)
Inventor
Charles N Serhan
Clary B Clish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU3846801A publication Critical patent/AU3846801A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU3846801A 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators Pending AU3846801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US23881400P 2000-10-06 2000-10-06
PCT/US2001/005196 WO2001060778A2 (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators

Publications (1)

Publication Number Publication Date
AU3846801A true AU3846801A (en) 2001-08-27

Family

ID=26878731

Family Applications (4)

Application Number Title Priority Date Filing Date
AU3846801A Pending AU3846801A (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators
AU2001238468A Expired AU2001238468B2 (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators
AU2006225252A Expired AU2006225252B2 (en) 2000-02-16 2006-10-05 Aspirin-triggered lipid mediators
AU2009202071A Expired AU2009202071B2 (en) 2000-02-16 2009-05-26 Aspirin-triggered lipid mediators

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2001238468A Expired AU2001238468B2 (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators
AU2006225252A Expired AU2006225252B2 (en) 2000-02-16 2006-10-05 Aspirin-triggered lipid mediators
AU2009202071A Expired AU2009202071B2 (en) 2000-02-16 2009-05-26 Aspirin-triggered lipid mediators

Country Status (11)

Country Link
US (5) US6670396B2 (enExample)
EP (2) EP1296923B3 (enExample)
JP (5) JP4932116B2 (enExample)
CN (4) CN102010324B (enExample)
AT (2) ATE504557T1 (enExample)
AU (4) AU3846801A (enExample)
CA (1) CA2400462C (enExample)
DE (2) DE60144401D1 (enExample)
IL (1) IL151299A0 (enExample)
MX (1) MXPA02007915A (enExample)
WO (1) WO2001060778A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
MXPA03007609A (es) * 2001-02-27 2004-06-30 Univ Michigan Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
ES2344814T3 (es) 2001-03-02 2010-09-07 The Brigham And Women's Hospital Analogos de lipoxina como nuevos inhibidores de la angiogenesis.
JP2005508282A (ja) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル 新規な脈管形成抑制剤としてのリポキシン類似物
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
JPWO2002102364A1 (ja) * 2001-06-18 2004-09-30 山田　幸子 ＰＰＡＲγ作動性医薬組成物
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
SI2022775T1 (sl) * 2002-04-01 2015-03-31 University Of Southern California Trihidroksi polinenasiäśeni eikosanoidi
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
DE60318456T2 (de) 2002-06-17 2008-12-24 Resolvyx Pharmaceuticals, Bedford ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1641352B2 (en) * 2003-07-07 2019-06-19 Hill's Pet Nutrition, Inc. Compositions for improved oxidative status in cats
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
DE14172396T1 (de) * 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
WO2007090162A2 (en) * 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
WO2008011085A1 (en) * 2006-07-19 2008-01-24 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
US20110190389A1 (en) * 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
KR20150115959A (ko) * 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2324827A4 (en) * 2008-08-22 2012-04-25 Mochida Pharm Co Ltd THERAPEUTIC ACTIVE FOR ANCA-ASSOCIATED VASCULITIDES
US8927747B2 (en) * 2008-09-16 2015-01-06 The Brigham And Women's Hospital, Inc. 14-hydroxy-docosahexaenoic acid compounds
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2010095706A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JP2013500966A (ja) * 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
FR2979824A1 (fr) * 2011-09-13 2013-03-15 Vetinnov Composition a usage humain ou veterinaire.
JP5969186B2 (ja) * 2011-09-15 2016-08-17 出光興産株式会社 Ｇｐｒ１１９アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
JP6173352B2 (ja) 2012-02-15 2017-08-02 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2014218666B2 (en) * 2013-02-22 2018-11-01 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
JP6295278B2 (ja) 2013-02-28 2018-03-14 アニダ ファーマ インコーポレイテッド 聴器毒性を治療する方法
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
WO2015185698A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2895062T3 (es) 2015-03-18 2022-02-17 Forsyth Dental Infirmary For Children Métodos para estabilizar placas ateroscleróticas usando lipoxinas, resolvinas y análogos de las mismas
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US11903998B2 (en) 2016-05-27 2024-02-20 Forsyth Dental Infirmary For Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN105924338B (zh) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 丁醇尾气回收工艺与系统
EP3475442B1 (en) * 2016-06-23 2024-10-23 The Regents of The University of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
CA3055093A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (ko) 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
WO2020076578A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
AU2019387329B2 (en) * 2018-11-30 2025-05-15 Evonik Operations Gmbh Preparation comprising a probiotic strain of the genus bacillus megaterium and a polyunsaturated fatty acid component
EP3946308A4 (en) * 2019-04-04 2022-12-14 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2021054778A1 (ko) * 2019-09-20 2021-03-25 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
BR112022020012A2 (pt) * 2020-04-03 2022-12-13 Afimmune Ltd Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) * 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
AU8083691A (en) * 1990-05-07 1991-11-27 Barry I. Bockow Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (ja) 1990-05-16 1992-01-28 Mitsubishi Electric Corp マイクロ波半導体装置
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
SG44524A1 (en) 1991-06-24 1997-12-19 Adelaide Children S Hospital Methods and compositions of treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (ja) 1993-11-19 1996-09-18 日本電気株式会社 モ―ルド型半導体装置
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
EP0923544B1 (en) 1996-06-28 2008-10-15 University of Southern California Method for the synthesis of amines and amino acids with organoboron derivatives
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
WO2000024510A1 (en) 1998-10-23 2000-05-04 University Of Southern California Combinatorial approach to chiral reagents or catalysts having amine or amino alcohol ligands
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
WO2000054767A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
EP1165809A2 (en) 1999-03-18 2002-01-02 The Brigham And Women's Hospital, Inc. Leukotriene b4 receptor transgenic mammals
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
JP2005508282A (ja) 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル 新規な脈管形成抑制剤としてのリポキシン類似物
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003051350A1 (en) 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
WO2003053423A2 (en) 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
SI2022775T1 (sl) * 2002-04-01 2015-03-31 University Of Southern California Trihidroksi polinenasiäśeni eikosanoidi
DE60318456T2 (de) 2002-06-17 2008-12-24 Resolvyx Pharmaceuticals, Bedford ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2004263164A1 (en) 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration
EP1755537A4 (en) 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2008011085A1 (en) 2006-07-19 2008-01-24 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
IL151299A0 (en) 2003-04-10
AU2001238468B2 (en) 2006-07-06
ATE344226T1 (de) 2006-11-15
JP2010248213A (ja) 2010-11-04
MXPA02007915A (es) 2005-06-20
WO2001060778A2 (en) 2001-08-23
US7737178B2 (en) 2010-06-15
US20100216882A1 (en) 2010-08-26
DE60144401D1 (de) 2011-05-19
US20020055538A1 (en) 2002-05-09
AU2006225252B2 (en) 2009-02-26
ATE504557T1 (de) 2011-04-15
CN1202068C (zh) 2005-05-18
EP1762557A3 (en) 2007-11-07
CN1951899B (zh) 2012-02-01
JP2016006057A (ja) 2016-01-14
CN1951899A (zh) 2007-04-25
CN1469858A (zh) 2004-01-21
CA2400462A1 (en) 2001-08-23
US20090149538A1 (en) 2009-06-11
CN102010324A (zh) 2011-04-13
CN100357244C (zh) 2007-12-26
US20040059144A1 (en) 2004-03-25
US7709669B2 (en) 2010-05-04
JP4932116B2 (ja) 2012-05-16
AU2006225252A2 (en) 2006-11-02
JP2019108348A (ja) 2019-07-04
DE60124256T2 (de) 2007-05-31
JP2015007046A (ja) 2015-01-15
CA2400462C (en) 2011-09-27
EP1296923B1 (en) 2006-11-02
AU2006225252A1 (en) 2006-11-02
AU2009202071A1 (en) 2009-06-18
EP1762557B1 (en) 2011-04-06
US6670396B2 (en) 2003-12-30
US8349896B2 (en) 2013-01-08
HK1105948A1 (en) 2008-02-29
JP2003525880A (ja) 2003-09-02
DE60124256D1 (de) 2006-12-14
WO2001060778A3 (en) 2003-01-16
AU2009202071B2 (en) 2011-07-07
DE60124256T3 (de) 2012-09-20
EP1296923B3 (en) 2012-04-11
CN102010324B (zh) 2014-04-02
US20070049639A1 (en) 2007-03-01
US7053230B2 (en) 2006-05-30
EP1762557A2 (en) 2007-03-14
CN1680259A (zh) 2005-10-12
EP1296923A2 (en) 2003-04-02
JP5973503B2 (ja) 2016-08-23
WO2001060778A9 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
AU3846801A (en) Aspirin-triggered lipid mediators
WO2003014156A3 (en) NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES
WO2001049298A3 (fr) Nouvelle application therapeutique de l"enoxaparine
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
TH9901003087A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001448A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001679A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001531A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001508A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001441A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901001091A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901000861A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901000715A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901000514A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901000201A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9903000134A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9903000108A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003923A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003753A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003712A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003710A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003619A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901003203A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901002661A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9901000476A (th) สิทธิบัตรยังไม่ประกาศโฆษณา